View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 14, 2022

miR Scientific announces commercial launch of miR Sentinel

miR Sentinel is designed to evaluate the risk of aggressive prostate cancer.

miR Scientific has announced the commercial launch of its miR Sentinel Prostate Cancer Test in the US, Puerto Rico and some international markets. 

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

A urine-based molecular test, miR Sentinel leverages a biostatistical algorithm to evaluate small non-coding RNA.

Designed to help in the clinical management of men over 45 years old, the test can evaluate the risk of aggressive prostate cancer.

In a study group involving around 1,100 male participants, the miR Sentinel Test was found to have detected molecular proof of prostate cancer in at-risk men with a 98.5% sensitivity. It also showed an 83% prognostic sensitivity in differentiating clinically non-significant from clinically significant prostate cancers.

The results of this recent clinical study, which was carried out at several locations within the US and Puerto Rico, were presented at the 2022 American Urological Association’s Annual Meeting. 

miR Scientific chairman and CEO Sam Salman said: “We believe that the miR Sentinel Test offers patients and providers a non-invasive means of accurately assessing a man’s prostate cancer risk, which could potentially reduce unnecessary biopsies and biopsy-related complications in men with low risk of clinically significant prostate cancer while prioritising diagnostic and treatment resources to those men that potentially harbour clinically significant prostate cancer. 

“This aligns with miR Scientific ‘s vision to revolutionise prostate cancer disease management by improving accessibility and accuracy of the tools used to assess each man’s personal risk of aggressive disease.”

The present version of the miR Sentinel Test is a clinically validated assessment developed for commercialisation based on the company’s miR Sentinel PCC4 assay.

This assay secured Breakthrough Device Designation from the US Food and Drug Administration (FDA ) in Q3 2020.

Related Companies

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network